Plain-English translation of NCT06123338 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing combined with two other medications ( and chemotherapy) to treat a specific type of stomach and esophageal cancer that has a genetic marker called HER2+. You would receive this medication combination before surgery to shrink the tumor, then continue treatment after surgery for a total of one year. The goal is to see if this three-drug approach works better than standard treatment alone.
Standard treatments for HER2+ stomach and esophageal cancer don't work well enough for many patients. Researchers believe that combining this newer immunotherapy medication with two proven cancer drugs might help more people survive longer and have better outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the three medications in cycles over about 5 months before your surgery. After surgery, you would continue receiving the same medications for additional cycles, with the goal of completing one year of total treatment. You'll have regular clinic visits for infusions, blood tests, and check-ups to monitor how you're responding and to watch for side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States